GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (FRA:GHDN) » Definitions » Cyclically Adjusted Book per Share

Brainstorm Cell Therapeutics (FRA:GHDN) Cyclically Adjusted Book per Share : €0.44 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Brainstorm Cell Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Brainstorm Cell Therapeutics's adjusted book value per share for the three months ended in Mar. 2024 was €-0.075. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.44 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Brainstorm Cell Therapeutics's average Cyclically Adjusted Book Growth Rate was -4.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 4.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Brainstorm Cell Therapeutics was 70.50% per year. The lowest was 4.60% per year. And the median was 13.40% per year.

As of today (2024-06-06), Brainstorm Cell Therapeutics's current stock price is €0.3945. Brainstorm Cell Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €0.44. Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio of today is 0.90.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Brainstorm Cell Therapeutics was 1.51. The lowest was 0.00. And the median was 0.00.


Brainstorm Cell Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Brainstorm Cell Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brainstorm Cell Therapeutics Cyclically Adjusted Book per Share Chart

Brainstorm Cell Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.29 0.36 0.42 0.43 0.40

Brainstorm Cell Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.45 0.45 0.40 0.44

Competitive Comparison of Brainstorm Cell Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio falls into.



Brainstorm Cell Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Brainstorm Cell Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.075/131.7762*131.7762
=-0.075

Current CPI (Mar. 2024) = 131.7762.

Brainstorm Cell Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.519 100.560 0.680
201409 0.454 100.428 0.596
201412 0.354 99.070 0.471
201503 0.988 99.621 1.307
201506 0.860 100.684 1.126
201509 0.748 100.392 0.982
201512 0.696 99.792 0.919
201603 0.605 100.470 0.794
201606 0.566 101.688 0.733
201609 0.502 101.861 0.649
201612 0.502 101.863 0.649
201703 0.412 102.862 0.528
201706 0.346 103.349 0.441
201709 0.231 104.136 0.292
201712 0.262 104.011 0.332
201803 0.163 105.290 0.204
201806 0.533 106.317 0.661
201809 0.413 106.507 0.511
201812 0.212 105.998 0.264
201903 0.013 107.251 0.016
201906 -0.184 108.070 -0.224
201909 -0.272 108.329 -0.331
201912 -0.475 108.420 -0.577
202003 0.287 108.902 0.347
202006 0.294 108.767 0.356
202009 0.699 109.815 0.839
202012 0.829 109.897 0.994
202103 0.837 111.754 0.987
202106 0.690 114.631 0.793
202109 0.584 115.734 0.665
202112 0.470 117.630 0.527
202203 0.361 121.301 0.392
202206 0.204 125.017 0.215
202209 0.038 125.227 0.040
202212 -0.078 125.222 -0.082
202303 -0.118 127.348 -0.122
202306 -0.088 128.729 -0.090
202309 -0.053 129.860 -0.054
202312 -0.074 129.419 -0.075
202403 -0.075 131.776 -0.075

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Brainstorm Cell Therapeutics  (FRA:GHDN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.3945/0.44
=0.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Brainstorm Cell Therapeutics was 1.51. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Brainstorm Cell Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Brainstorm Cell Therapeutics (FRA:GHDN) Business Description

Traded in Other Exchanges
Address
1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Brainstorm Cell Therapeutics (FRA:GHDN) Headlines

No Headlines